Malaria causes much physical and economic hardship in tropical regions, particularly in
communities where medical care is rudimentary. Should a vaccine be developed, it is the …

Malaria is a vector‐borne infectious disease caused by unicellular parasites of the genus
Plasmodium. These obligate intracellular parasites have the unique capacity to infect and …

Background Surrogate markers of protective immunity to malaria in humans are needed to
rationalize malaria vaccine discovery and development. In an effort to identify such markers …

Plasmodium parasites are the causative agent of human malaria, and the development of a
highly effective vaccine against infection, disease and transmission remains a key priority. It …

Background GMZ2 is a recombinant protein malaria vaccine, comprising two blood-stage
antigens of Plasmodium falciparum, glutamate-rich protein and merozoite surface protein 3 …

Large gains in the reduction of malaria mortality in the early 20th century were lost in
subsequent decades. Malaria now kills 2–3 million people yearly. Implementation of malaria …

Between 1996 and 2001, the prevalence of placental malaria in pregnant women living in
Yaounde, Cameroon and its effect on pregnancy outcome were evaluated with respect to …

There is longstanding evidence that immunoglobulin G (IgG) has a role in protection against
clinical malaria, and human antibodies of the cytophilic subclasses are thought to be …

Naturally acquired immunity (NAI) to Plasmodium falciparum malaria is mainly mediated by
IgG antibodies but the subclasses, epitope targets and effector functions have not been …

Background Antigen-specific antibody-mediated immune responses play an important role
in natural protection against clinical malaria, but conflicting estimates of this association …